Danicopan serves as an oral complement Factor D inhibitor, indicated as an add-on therapy alongside ravulizumab or eculizumab for adults managing paroxysmal nocturnal haemoglobinuria (PNH). This category… Read more
Danicopan serves as an oral complement Factor D inhibitor, indicated as an add-on therapy alongside ravulizumab or eculizumab for adults managing paroxysmal nocturnal haemoglobinuria (PNH). This category offers a comprehensive selection of high-quality reference materials, including the Danicopan active pharmaceutical ingredient, its specific impurities, and stable isotope labelled compounds. Pharmaceutical laboratories utilize these reference standards to conduct rigorous impurity profiling, method validation, and routine quality control testing. By providing precise, well-characterized materials, this collection supports the development and regulatory compliance of analytical methods necessary for ensuring the safety and efficacy of the drug substance. Whether performing quantitative analysis or monitoring degradation pathways, analysts rely on these compounds to maintain accuracy in complex pharmaceutical evaluations and structural characterization studies.